Healthcare Industry News: Abbott
News Release - January 10, 2013
Pathway Genomics Names Todd G. Johnson as Vice President of Sales and MarketingSAN DIEGO--(Healthcare Sales & Marketing Network)--Pathway Genomics Corporation, a San Diego-based clinical laboratory that offers genetic testing services internationally, today announced it has appointed Todd G. Johnson, MBA, as vice president of sales and marketing. Based at Pathway Genomics’ San Diego headquarters, in this executive management position, Johnson will assume responsibility for leading the company’s domestic sales division, as well as its marketing and client services teams.
“Todd has a wealth of experience in diagnostics and CLIA laboratories, and has managed sales teams of more than 100 individuals at world-class companies,” said Jim Plante, Pathway Genomics’ founder and CEO.
Johnson brings over two decades of sales and marketing experience to Pathway Genomics. Prior to joining the company, he served in various sales and marketing leadership roles for medical device and service companies, including Abbott Laboratories (Diagnostic Division), Ventana Medical Systems, Biocept Laboratories, Insight Health and LabCorp. He has functioned as an executive with small biotech to multibillion-dollar firms with revenues exceeding $500 million annually and has supervised more than 135 sales and marketing personnel.
“Pathway Genomics possesses a truly client-focused culture that is committed to accuracy and medical responsibility,” said Johnson. “My goal is to strengthen its evolution into a leader in genetic testing.”
Johnson has a Bachelor of Science degree from the United States Military Academy at West Point, an MBA from Webster University, and he served globally in the United States Army as a helicopter pilot.
About Pathway Genomics
Pathway Genomics owns and operates an on-site genetic testing laboratory that is accredited by the College of American Pathologists (CAP), accredited in accordance with the U.S. Health and Human Services’ Clinical Laboratory Improvement Amendments (CLIA) of 1988, and licensed by the state of California. Using only a saliva sample, the company incorporates customized and scientifically validated technologies to generate personalized reports, which address a variety of medical issues, including an individual’s carrier status for recessive genetic conditions, food metabolism and exercise response, prescription drug response, and propensity to develop certain diseases such as heart disease, type 2 diabetes and cancer. For more information about Pathway Genomics, visit www.pathway.com.
Source: Pathway Genomics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.